ScoreWhy is Aclaris Therapeutics, Inc. ?
1
Poor long term growth as Operating profit has grown by an annual rate -13.75% of over the last 5 years
2
The company has declared Negative results for the last 5 consecutive quarters
- NET SALES(HY) At USD 3.29 MM has Grown at -69.14%
- DEBTORS TURNOVER RATIO(HY) Lowest at 3.3 times
- PRE-TAX PROFIT(Q) Lowest at USD -19.82 MM
3
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of 233.79%, its profits have fallen by -55.9%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Aclaris Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Aclaris Therapeutics, Inc.
253.96%
3.57
99.82%
S&P 500
22.24%
1.91
13.23%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
3.86%
EBIT Growth (5y)
-13.75%
EBIT to Interest (avg)
-71.59
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.73
Sales to Capital Employed (avg)
0.16
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
86.14%
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
4.12
EV to EBIT
-4.53
EV to EBITDA
-4.57
EV to Capital Employed
25.95
EV to Sales
42.72
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-573.47%
ROE (Latest)
-60.56%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bullish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
NET PROFIT(HY)
Higher at USD -39.22 MM
RAW MATERIAL COST(Y)
Fallen by -281.5% (YoY
-21What is not working for the Company
NET SALES(HY)
At USD 3.29 MM has Grown at -69.14%
DEBTORS TURNOVER RATIO(HY)
Lowest at 3.3 times
PRE-TAX PROFIT(Q)
Lowest at USD -19.82 MM
NET PROFIT(Q)
Lowest at USD -19.82 MM
Here's what is working for Aclaris Therapeutics, Inc.
Raw Material Cost
Fallen by -281.5% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Aclaris Therapeutics, Inc.
Net Sales
At USD 3.29 MM has Grown at -69.14%
Year on Year (YoY)MOJO Watch
Near term sales trend is very negative
Net Sales (USD MM)
Pre-Tax Profit
Lowest at USD -19.82 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Pre-Tax Profit
At USD -19.82 MM has Fallen at -27.03%
over average net sales of the previous four periods of USD -15.61 MMMOJO Watch
Near term Pre-Tax Profit trend is negative
Pre-Tax Profit (USD MM)
Net Profit
Lowest at USD -19.82 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Net Profit
At USD -19.82 MM has Fallen at -27.03%
over average net sales of the previous four periods of USD -15.61 MMMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
Debtors Turnover Ratio
Lowest at 3.3 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling Debtors has slowed
Debtors Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
